Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trialChuanhua Zhao, Chuan Jin, Weiqing Chen et al.|Signal Transduction and Targeted Therapy|2025Cited by 20
Corrigendum: Pan-Cancer Analysis Shows That ALKBH5 Is a Potential Prognostic and Immunotherapeutic Biomarker for Multiple Cancer Types Including GliomasCheng Wei, Jianning Zhang, Bo Wang et al.|Frontiers in Immunology|2022Cited by 2